-
Je něco špatně v tomto záznamu ?
The foggy world(s) of p63 isoform regulation in normal cells and cancer
Z. Pokorná, J. Vysloužil, V. Hrabal, B. Vojtěšek, PJ. Coates
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
33638205
DOI
10.1002/path.5656
Knihovny.cz E-zdroje
- MeSH
- lidé MeSH
- nádorové supresorové proteiny * MeSH
- nádory * MeSH
- protein - isoformy MeSH
- transkripční faktory * MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
The p53 family member p63 exists as two major protein variants (TAp63 and ΔNp63) with distinct expression patterns and functional properties. Whilst downstream target genes of p63 have been studied intensively, how p63 variants are themselves controlled has been relatively neglected. Here, we review advances in understanding ΔNp63 and TAp63 regulation, highlighting their distinct pathways. TAp63 has roles in senescence and metabolism, and in germ cell genome maintenance, where it is activated post-transcriptionally by phosphorylation cascades after DNA damage. The function and regulation of TAp63 in mesenchymal and haematopoietic cells is less clear but may involve epigenetic control through DNA methylation. ΔNp63 functions to maintain stem/progenitor cells in various epithelia and is overexpressed in squamous and certain other cancers. ΔNp63 is transcriptionally regulated through multiple enhancers in concert with chromatin modifying proteins. Many signalling pathways including growth factors, morphogens, inflammation, and the extracellular matrix influence ΔNp63 levels, with inconsistent results reported. There is also evidence for reciprocal regulation, including ΔNp63 activating its own transcription. ΔNp63 is downregulated during cell differentiation through transcriptional regulation, while post-transcriptional events cause proteasomal degradation. Throughout the review, we identify knowledge gaps and highlight discordances, providing potential explanations including cell-context and cell-matrix interactions. Identifying individual p63 variants has roles in differential diagnosis and prognosis, and understanding their regulation suggests clinically approved agents for targeting p63 that may be useful combination therapies for selected cancer patients. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
Research Centre of Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012370
- 003
- CZ-PrNML
- 005
- 20220506130042.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/path.5656 $2 doi
- 035 __
- $a (PubMed)33638205
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pokorná, Zuzana $u Research Centre of Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic $1 https://orcid.org/0000000181742521
- 245 14
- $a The foggy world(s) of p63 isoform regulation in normal cells and cancer / $c Z. Pokorná, J. Vysloužil, V. Hrabal, B. Vojtěšek, PJ. Coates
- 520 9_
- $a The p53 family member p63 exists as two major protein variants (TAp63 and ΔNp63) with distinct expression patterns and functional properties. Whilst downstream target genes of p63 have been studied intensively, how p63 variants are themselves controlled has been relatively neglected. Here, we review advances in understanding ΔNp63 and TAp63 regulation, highlighting their distinct pathways. TAp63 has roles in senescence and metabolism, and in germ cell genome maintenance, where it is activated post-transcriptionally by phosphorylation cascades after DNA damage. The function and regulation of TAp63 in mesenchymal and haematopoietic cells is less clear but may involve epigenetic control through DNA methylation. ΔNp63 functions to maintain stem/progenitor cells in various epithelia and is overexpressed in squamous and certain other cancers. ΔNp63 is transcriptionally regulated through multiple enhancers in concert with chromatin modifying proteins. Many signalling pathways including growth factors, morphogens, inflammation, and the extracellular matrix influence ΔNp63 levels, with inconsistent results reported. There is also evidence for reciprocal regulation, including ΔNp63 activating its own transcription. ΔNp63 is downregulated during cell differentiation through transcriptional regulation, while post-transcriptional events cause proteasomal degradation. Throughout the review, we identify knowledge gaps and highlight discordances, providing potential explanations including cell-context and cell-matrix interactions. Identifying individual p63 variants has roles in differential diagnosis and prognosis, and understanding their regulation suggests clinically approved agents for targeting p63 that may be useful combination therapies for selected cancer patients. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory $7 D009369
- 650 _2
- $a protein - isoformy $7 D020033
- 650 12
- $a transkripční faktory $7 D014157
- 650 12
- $a nádorové supresorové proteiny $7 D025521
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vysloužil, Jan $u Research Centre of Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Hrabal, Václav $u Research Centre of Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Vojtěšek, Borˇivoj $u Research Centre of Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 700 1_
- $a Coates, Philip J $u Research Centre of Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic
- 773 0_
- $w MED00002878 $t The Journal of pathology $x 1096-9896 $g Roč. 254, č. 4 (2021), s. 454-473
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33638205 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130035 $b ABA008
- 999 __
- $a ok $b bmc $g 1789806 $s 1163571
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 254 $c 4 $d 454-473 $e 20210407 $i 1096-9896 $m Journal of pathology $n J Pathol $x MED00002878
- LZP __
- $a Pubmed-20220425